The study is the first publication to emerge from the company's ongoing prospective study, Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR). The study found that AROA's Myriad Matrix ...

The study is the first publication to emerge from the company's ongoing prospective study, Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR). The study found that AROA's Myriad Matrix ...

Aroa Biosurgery product revenue up 27% to NZ$39.1 million on constant currency basis in H1 FY25 Myriad sales surge 45% in H1 FY25, accounting for 38% of total sales and 72% of direct sales mix ...

Aroa Biosurgery’s latest study shows potential of Myriad treatment range to save limbs and cut costs in high-risk surgeries. Aroa Biosurgery (ASX: ARX) has announced the publication of the first ...

Aroa Biosurgery (ASX: ARX) has announced the publication of the first results from its Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), which has shown significant promise in ...